In this article:

United Therapeutics (UTHR) Gets a Hold Rating from BTIG

In this article:
In this article:

BTIG analyst Julian Harrison maintained a Hold rating on United Therapeutics (UTHRResearch Report) on March 9. The company’s shares closed last Friday at $181.20.

According to TipRanks.com, Harrison is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -17.8% and a 37.5% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Prometheus Biosciences, and Aerovate Therapeutics.

Currently, the analyst consensus on United Therapeutics is a Strong Buy with an average price target of $235.83.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $218.38 and a one-year low of $158.38. Currently, United Therapeutics has an average volume of 425.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Read More on UTHR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed